No Data
Adverum Biotechnologies Initiated at Outperform by Oppenheimer
Oppenheimer Initiates Adverum Biotechnologies(ADVM.US) With Buy Rating, Announces Target Price $25
Express News | Adverum Biotechnologies Inc : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $25
Adverum Biotechnologies to Participate in TD Cowen's Genetic Medicines & RNA Summit
Express News | Adverum Biotechnologies Announces Appointments of DR. Rabia Gurses Ozden as Chief Medical Officer and DR. Szilárd Kiss as a Member of the Board of Directors
Strong Buy Rating for Adverum Biotechnologies Amid Anticipated Positive Phase 2 Results and Market Undervaluation